Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda

Junji Furuse

Yokohama, JP 
Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Junji Furuse practices in Yokohama, Japan. Furuse is rated as an Experienced expert by MediFind in the treatment of X-Linked Spondyloepiphyseal Dysplasia Tarda. Their top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 279 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have participated in 2 clinical trials in the study of X-Linked Spondyloepiphyseal Dysplasia Tarda.

Locations

Yokohama, Japan
Other Locations
Tokyo, Japan
Chuo, 1040045, Japan
Kanagawa, 2418515, Japan
Mitaka, Japan
Japan
Shizuoka, 4118777, Japan
Sayama, Japan
Kashiwa, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Enrollment Status: Completed
Publish Date: December 05, 2022
View 2 Less Clinical Trials

279 Total Publications

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Furuse's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile